![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
November 21, 2025
This clinical trial is exploring whether PARP inhibitors will improve outcomes for patients with early-stage pancreas cancer that has BRCA or PALB2 mutations
August 28, 2025
This study is now assessing blood-based and imaging biomarkers to identify patients at elevated risk of pancreatic cysts becoming cancerous
February 19, 2025
Seven ground-breaking findings from cancer clinical trials in 2024 by ECOG-ACRIN and PrECOG
June 11, 2024
Summaries of five ECOG-ACRIN trials presented at the 2024 American Society of Clinical Oncology Annual Meeting
August 25, 2023
The GIANT trial (EA2186) is the first randomized clinical trial to focus on vulnerable older adults with treatment-naïve metastatic pancreatic cancer who are not candidates for standard therapy.
April 19, 2023
This phase 2 study is exploring whether the addition of maintenance PARP inhibition for BRCA- or PALB2-mutated pancreatic cancer improves outcomes
February 10, 2023
Summaries of recently published ECOG-ACRIN research results
April 15, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
August 17, 2021
This study is evaluating two different screening strategies for non-cancerous pancreatic cysts; recently activated amendment #2 expands the eligibility criteria
July 7, 2021
The GIANT trial (EA2186) is the first randomized clinical trial to focus on vulnerable older adults with treatment-naïve metastatic pancreatic cancer who are not candidates for standard therapy
May 28, 2021
This phase II study, led by Dr. Kim Reiss Binder, is exploring whether the addition of maintenance PARP inhibition for BRCA- or PALB2-mutated pancreatic cancer improves outcomes
July 29, 2020
Currently, there is no treatment standard for metastatic pancreatic cancer in people aged 65 years and older